The anti-obesity drugs market is expected to register a CAGR of 15% over the forecast period, 2022-2027. During the COVID-19 situation, it was observed that obesity had increased exponentially. As per an article published by the European Journal of Nutrition in December 2020, the rate of obesity has increased in the world. The major reasons are a change in lifestyle and a decrease in exercise practice among people as they avoid gyms and yoga classes due to the social distancing protocols.

Similarly, according to the article published in the Diabetes Obesity and Metabolism in August 2021 titled "A global country-level analysis of the relationship between obesity and COVID-19 cases and mortality" obesity prevalence is a significant and potentially modifiable risk factor for increased COVID-19 national caseload and mortality. This increase in the obese population and COVID-19 mortality is expected to drive the demand for anti-obesity drugs in the near future.

According to the World Health Organization’s report published in June 2021, 39 million children under the age of 5 years were overweight or obese in 2020. One in five children and adolescents globally are overweight. Incidences of obesity have been increasing fiercely over the past decades, and it is often described as a global endemic, especially in developed countries where lifestyle-related disorders, such as anxiety, stress, smoking, and drinking, are more prevalent.

To know more: